{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:35:40Z","timestamp":1787654140002,"version":"build-2736575974"},"reference-count":22,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2266317","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:05:43Z","timestamp":1696334743000},"page":"1278-1286","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data"],"prefix":"10.1080","volume":"26","author":[{"given":"Sepehr","family":"Farahbakhshian","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals USA Inc, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Fan","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA Inc, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob G.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA Inc, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Princic","sequence":"additional","affiliation":[{"name":"Merative, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Park","sequence":"additional","affiliation":[{"name":"Merative, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bullano","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA Inc, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"e_1_3_7_2_1","unstructured":"Centers for Disease Control and Prevention. Data and Statistics on Hemophilia; 2022. Available from: https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/data.html"},{"key":"e_1_3_7_3_1","unstructured":"National Organization for Rare Disorders. Hemophilia A. Rare Disease Database; Updated 2021. Available from https:\/\/rarediseases.org\/rare-diseases\/hemophilia-a\/"},{"key":"e_1_3_7_4_1","volume-title":"StatPearls","author":"Salen P","year":"2022","unstructured":"Salen P, Babiker HM, Hemophilia A. StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2022."},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"issue":"5","key":"e_1_3_7_8_1","first-page":"S126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen SL.","year":"2016","unstructured":"Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manage Care. 2016;22(5):S126\u2013S133.","journal-title":"Am J Manage Care"},{"issue":"6","key":"e_1_3_7_9_1","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort L","year":"2019","unstructured":"Aledort L, Mannucci PM, Schramm W, et\u00a0al. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479\u2013486.","journal-title":"Blood Transfus"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13758"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25844"},{"key":"e_1_3_7_12_1","unstructured":"U.S. Food and Drug Administration. Antihemophilic factor (recombinant) PEGylated (Adynovate) prescibing infomation. 2022. Available from: https:\/\/www.fda.gov\/media\/102389\/download"},{"key":"e_1_3_7_13_1","unstructured":"U.S. Food and Drug Administration. Antihemophilic factor (recombinant) Fc fusion protein (Eloctate) prescibing information. 2022. Available from: https:\/\/www.fda.gov\/media\/88746\/download"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1016228"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.3.316"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13220"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.412"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21368"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14469"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12476"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_3_7_22_1","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index\u2014all urban consumers US medical care 2020. 2020. Available from: https:\/\/www.bls.gov\/cpi\/data.htm"},{"key":"e_1_3_7_23_1","unstructured":"AMCP. Summit on hemophilia: findings from the AMCP Market Insights Program. 2018. Available from: https:\/\/www.amcp.org\/Resource-Center\/meeting-proceedings-findings\/amcp-market-insights-summit-hemophilia"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2266317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:13:54Z","timestamp":1701944034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2266317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2266317"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2266317","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}